ARDT — what changed in the latest 10-Q
A section-by-section comparison of ARDT's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-06 vs the prior 10-Q · 2025-11-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +210 | −385 | ~87 | 260 |
| Market risk (Item 3) | Text added/removed | +6 | −9 | ~6 | 9 |
| Controls & procedures | Text added/removed | 0 | 0 | ~9 | 5 |
| Legal proceedings | Text added/removed | +4 | −2 | 0 | 0 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-06
discussion includes forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never
materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-
looking statements. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties
that could impact our business. In particular, we encourage you to review the risks and uncertainties described in the section
This Quarterly Report, including the following discussion, may contain certain "forward-looking statements," as that term is
Text removed vs the prior filing · source: 10-Q · 2025-11-14
for the year ended December 31, 2024 (the "Annual Report"). The following discussion includes forward-looking statements
that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our
results to differ materially from those expressed or implied by such forward-looking statements. When reviewing the
discussion below, you should keep in mind the substantial risks and uncertainties that could impact our business. In
particular, we encourage you to review the risks and uncertainties described in the section titled "Risk Factors" included in
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-05-06
accompanying condensed consolidated financial statements included elsewhere in this Quarterly Report for more information
on the interest rate swap agreements. Under the amended October 2021 Agreements, expiring June 30, 2026, we are required
to make monthly fixed rate payments at annual rates ranging from 1.47% to 1.48% and the counterparties are obligated to
make monthly floating rate payments to us based on one-month Term SOFR, each subject to a floor of 0.39%. Under the
February 2025 Agreements, expiring June 26, 2029, we are required to make monthly fixed rate payments at annual rates
Text removed vs the prior filing · source: 10-Q · 2025-11-14
Financial Statements included within this Quarterly Report for more information on the interest rate swap agreements. Under
the October 2021 Agreements, expiring June 30, 2026, we are required to make monthly fixed rate payments at annual rates
ranging from 1.47% to 1.48% and the counterparties are obligated to make monthly floating rate payments to us based on
one-month Term SOFR, each subject to a floor of 0.39%. On February 5, 2025, we executed new interest rate swap
agreements with an effective date of June 30, 2025 and expiring June 26, 2029. As of the effective date, the notional amounts
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-05-06
Because we provide healthcare services in a highly regulated industry, we have been, are, and expect to continue to be, party
to various lawsuits and regulatory investigations from time to time. Refer to the "Litigation and Regulatory Matters" section
of Note 9, Commitments and Contingencies, in the notes to the condensed consolidated financial statements contained
elsewhere in this Quarterly Report, which is incorporated by reference herein.
Text removed vs the prior filing · source: 10-Q · 2025-11-14
The information set forth in the “Litigation and Regulatory Matters” section of Note 9, Commitments and Contingencies, in
the notes to the unaudited condensed consolidated financial statements contained elsewhere in this Quarterly Report is
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice